In bovine and ovine practice, acute inorganic arsenic exposure from contaminated pasture, old dip residues, or medicated feed adulteration has historically been managed by intramuscular injection of dimercaprol at 2.5–5 mg/kg body weight, repeated every 4–6 h for the first 24 h, followed by interval extension based on urinary arsenic clearance and clinical status. The veterinary-grade API for this parenteral route is commonly incorporated into a sterile oily vehicle rather than an aqueous solution, because the dimercaprol molecule carries two free sulfhydryl groups that are highly susceptible to oxidative dimerization in the presence of water and atmospheric oxygen. A standard production sequence begins by dissolving dimercaprol in benzyl benzoate at approximately 20% w/v, then blending the resulting solution with refined peanut oil to a final drug concentration of 100 mg/mL. The presence of benzyl benzoate is not merely as a cosolvent; it lowers the oil-phase viscosity to a target fill viscosity below 50 mPa·s at 25 °C, permitting draw-up through 21 G needles without excessive backpressure on the syringe plunger. Nitrogen sparging of both the API phase and the oil phase is applied throughout the compounding process, and the filling line is maintained under a nitrogen overlay with headspace oxygen specified below 1.0% v/v in the finished vial. Sterilization is executed by passage through 0.22 µm polyvinylidene fluoride or polytetrafluoroethylene membranes; nylon membranes are avoided because of solvent-system compatibility risks. Terminal steam sterilization is generally not recommended for this dosage form because thiol degradation accelerates above 40 °C, producing the disulfide dimer with negligible chelation activity. Finished vials are sterile-filled into amber Type I glass with fluoropolymer-coated butyl rubber stoppers, and batch release includes sterility testing per USP <71>, particulate matter per USP <788>, and assay against the Dimercaprol Injection USP monograph. In production-scale veterinary filling lines, the principal batch-to-batch failure mode is not microbial contamination but oxidative color change from pale yellow to amber-brown, a visual marker of disulfide formation that necessitates additional nitrogen blanketing and shorter hold times in the holding vessel.

Tablet Compression of a Low-Dose Thiol API Requires Acidic Granulation and Controlled Humidity

Direct compression of the neat liquid dimercaprol active into tablet matrices is not technically feasible because the oily API does not flow, and its concentrated thiol groups can bind to metal tooling surfaces during compaction. The transition to a solid oral dosage form therefore starts with cold adsorption of dimercaprol onto anhydrous colloidal silicon dioxide at a ratio of 1:1 to 1:2, producing a free-flowing powder that can be blended with excipients. Granulation is performed with an anhydrous alcoholic solvent system, typically ethanol or isopropanol, because water introduced during aqueous granulation accelerates conversion of the active to its disulfide dimer and generates sticky granulations with poor compressibility. A representative low-dose tablet formula for canine or feline lead toxicosis contains anhydrous lactose and microcrystalline cellulose at a 3:1 filler ratio, 3.0% w/w povidone K30 binder, 2.0% w/w crospovidone disintegrant, and 1.0% w/w sodium stearyl fumarate lubricant. The lubricant selection avoids metallic stearates, not because magnesium stearate is chemically incompatible with the active, but because metal ions originating from tool wear or excipient traces can be chelated by dimercaprol, contributing to surface pitting and variable content uniformity. Vacuum drying at 30–35 °C is maintained until loss on drying is below 2.0% by USP <921>; higher residual moisture leads to progressive discoloration and soft tablets at compression forces of 8–15 kN. Compression on a rotary press with 9 mm round flat-faced beveled punches yields tablets with target hardness of 40–60 N and friability below 0.5% per USP <1216>. Because the odor of free thiols can trigger rejection by companion animals, the tablet cores are subsequently film-coated with an amino methacrylate copolymer, Eudragit E100, at 5% w/w weight gain using an acetone/isopropanol spray solution. This coating layer functions primarily as an odor barrier and only secondarily as a moisture shield. The same granulation can be filled into size 3 hard gelatin capsules at a fill weight of 120–150 mg; capsules are preferred for feline patients because the odor is fully enclosed and the dose can be dispersed in food. The oral route is used where injectable therapy cannot be continued; published veterinary protocols for lead poisoning often combine dimercaprol with calcium disodium edetate in acute cases, but tablet continuation must be adjusted against blood lead concentrations rather than fixed dosing schedules.

What Limits Granule Uniformity When Dimercaprol Is Sprayed onto Sugar Spheres?

When fluid-bed rotor processing is selected for avian oral granules, product temperature is held between 28 °C and 32 °C, because at product temperatures above 35 °C the thiol-bearing molecule begins to develop a yellow-orange oxidation band that later shifts granule assay and reduces chelation potency. Granule-based dosage forms for poultry, waterfowl, or psittacine birds are manufactured by spray layering the liquid dimercaprol API onto inert sugar spheres inside a fluid-bed rotor processor. Atomization air is maintained at 1.0–1.5 bar, and the spray rate is ramped from 4 g/min per kg of bed mass to 6 g/min per kg as the granule surface area increases. The spray solution consists of dimercaprol, 10% w/v ethylcellulose N7 as a sealing polymer, and 0.05% w/w butylated hydroxyanisole dissolved in acetone/ethanol; the antioxidant is included to scavenge free radicals generated at the spray nozzle. Sugar spheres with a starting particle size of 600–710 µm are preferred, because smaller cores produce excess fines during the tangential spray phase, while larger cores reduce surface drug loading below the 5% w/w target. After spraying, granules are dried to residual moisture below 2.0% Karl Fischer, then sieved to remove agglomerates above 1000 µm and fines below 710 µm. The granule intermediate is packed in aluminum-foil blisters with a desiccant sachet, and stability studies conducted at 25 °C/60% RH and 40 °C/75% RH monitor content uniformity, disintegration, and disulfide dimer formation. When the granule dose is prescribed as a powder for reconstitution, the fraction below 500 µm is milled and packed under nitrogen; the powder is reconstituted with an oily or glycol vehicle immediately before administration. A recurrent production failure occurs when fluidization air dew point is not controlled; if ambient humidity exceeds 60% RH during loading, the sugar spheres adsorb surface water, causing the ethylcellulose barrier to phase-separate and the dimercaprol layer to become tacky. Under those conditions, granules fuse into agglomerates and the batch must be re-sieved or rejected for poor blend uniformity.

Premix Carrier Chemistry in Trace Metal Exposure Events

In feed mills where a non-food dimercaprol premix is authorized under veterinary prescription, the liquid API is first adsorbed onto precipitated silica with a specific surface area of 150–250 m²/g at a ratio of 1:1.5, then blended with ground corn cob or rice hulls to produce a low-strength carrier of 0.5–2.0% w/w dimercaprol. Feed-premix application of dimercaprol for group medication is limited to specific non-food or zoological collection settings in many regulatory frameworks, and published data for this specific configuration is limited. A ribbon blender with a fill volume of 60–70% is used for the final dilution step, and blend uniformity is assessed by sampling at 10 positions after 10 min and 20 min of mixing, with an acceptance criterion of relative standard deviation below 5.0%. The premix cannot be introduced before steam conditioning or pelleting, because the combination of moisture and temperatures above 60 °C rapidly oxidizes the free sulfhydryl groups. Application must therefore occur by post-pelleting spray or by incorporation into a cold-extruded crumble if the dosage form is to retain activity. A further process incompatibility exists with standard mineral premixes: free copper, zinc, and iron in trace-mineral packs are chelated by dimercaprol at neutral intestinal pH, which not only reduces the intended metal-binding capacity of the antidote but also perturbs mineral bioavailability. Consequently, dimercaprol-containing premixes must be segregated from trace-mineral premixes at the feed mill, and flushing procedures using 20 kg of carrier per mixer cycle are applied before changing to a non-thiol feed. Residue withdrawal for food-producing species is not defined by a harmonized standard; operators must consult VICH GL 48 and national residue control programs before any potential food-animal application.

Compounded oral solutions for equine and zoological patients are prepared from dimercaprol API using non-aqueous vehicles that suppress both hydrolysis and oxidative degradation. A viable compounding formulation uses propylene glycol 60% v/v, polyethylene glycol 400 25% v/v, benzyl alcohol 1.5% v/v, and butylated hydroxyanisole 0.05% w/v; the API is added slowly under high-shear dispersion at 1000–1500 rpm until complete dissolution, then the solution is passed through a 5 µm clarifying filter into amber Type III glass bottles. pH adjustment is not applied because the solvent system is predominantly non-aqueous; if a small aqueous fraction is introduced for palatability, a citrate buffer system at pH 5.0–5.5 is required, since alkaline pH accelerates thiol ionization and disulfide formation. During bottle filling, headspace nitrogen flushing is performed to keep residual oxygen below 1.0% v/v, and bottles are closed with polypropylene caps lined with polytetrafluoroethylene. The compounded liquids are stored at 2–8 °C and assigned a beyond-use date not exceeding 14 days unless a stability-indicating assay justifies extension under the applicable compounding standard. The main physical failure mode in this dosage form is not precipitation, because dimercaprol is soluble in the chosen co-solvent system, but a slow increase in turbidity caused by trace metal chelation from glass or cap liner extraction. For that reason, empty container systems should be screened for extractable heavy metals using USP <660> for glass containers and USP <661> for plastic components before a specific compounding batch is initiated.

When Dimercaprol Is Formulated as a Sterile Parenteral, Which Filtration Sequence Prevents Sulfide Propagation?

A second parenteral manufacturing scenario arises when the dosage form is scaled from small-volume ampoules to multi-vial batches for companion-animal emergency chelation, where the process must control not only sterility but also the precipitation of heavy-metal sulfides that can form from trace metal impurities. The bulk solution is prepared in a closed stainless-steel vessel equipped with bottom-mounted magnetic drive, and the oil phase is degassed under vacuum at 200–500 mbar absolute pressure before API addition. The preferred filtration sequence is a depth prefilter of 1.0 µm followed by two 0.22 µm sterilizing-grade membranes arranged in series, because the dimercaprol vehicle may shed trace polymeric particulates during prolonged mixing. Filter integrity testing is performed by the forward-flow method before and after filling, with diffusion limits established by the manufacturer for the specific membrane lot. The filling line is configured with pre- and post-fill nitrogen tunnels, and the filling pump uses ceramic rotary pistons rather than stainless steel, because the API can chelate iron and chromium ions from stainless steel wetted parts over extended campaigns. Vials are sealed with 20 mm fluoropolymer-coated butyl stoppers under a continuous nitrogen curtain. The aseptic process simulation for this line requires a media fill of not fewer than 5000 units per chamber according to EU GMP Annex 1, and the environmental monitoring plan includes settle plates and active microbial air sampling in the vicinity of the filling needles. In addition to sterility, release testing includes subvisible particulate matter per USP <788>, viscosity according to Ph. Eur. 2.2.9, and container-closure integrity under vacuum decay per ASTM F2338-09. The primary batch failure mode observed in multi-vial parenteral campaigns is oxidative color drift in the holding tank, which is controlled by limiting bulk hold time to 8 h and maintaining the solution under 10–15 °C during recirculation.